Respira Therapeutics has announced that United Therapeutics will fund the development of Respira’s RT234 DPI for the treatment of pulmonary hypertension.
United Therapeutics will get an exclusive license for the product in North America and will be the lead investor in Respira’s Series B financing round. Respira will continue to develop RT234 for other indications. No additional terms of the deal were disclosed.
United Therapeutics Chairman and CEO Martine Rothblatt said, “We are very pleased to extend our leadership in pulmonary hypertension by collaborating with Respira on inhaled RT234. We believe that Respira’s novel technology will enable us to continue providing more oral and inhaled medicines to more pulmonary hypertension patients in the USA than any other company.”
Respira President and CEO Bob Curtis commented, “Respira is very excited to be working with United Therapeutics, arguably the leading pulmonary hypertension pharmaceutical company in the world. We share a common commitment to develop disruptive therapeutic approaches that can translate into disease-altering medicines for patients with pulmonary hypertension and other diseases. This important investment and strategic collaboration will allow our company to capitalize on the innovative research pipeline we have developed. We share United Therapeutics’ aims and values, and we could not be more pleased to have them as a collaborator in our efforts.”
Read the Respira Therapeutics press release.
